Home › Indigestion › NCT06241183

Famotidine and Antacids for Treatment of Dyspepsia

Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Subject Age ≥ 18 years of age
2. Patient diagnosed with dyspepsia
3. Present at the ED with upper abdominal pain score of at least 3

Exclusion Criteria:

1. Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
2. Moderate to Severe Renal Insufficiency (precaution)
3. Kidney Failure
4. Pregnant or Nursing
5. Verbal pain score less than 3
6. Inability to tolerate oral medications
7. Bowel Obstruction
8. Proton pump inhibitor within 2 hours of study treatment

About the study

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

What is being tested

• Intravenous Famotidine (drug)
• Oral Maalox/ Mylanta (drug)

Sponsor: Stony Brook University · Participants: 80 · Started: Nov 9, 2023

Contact the study team

• Adam Singer, MD · Phone: 6314447857

Official record on ClinicalTrials.gov — NCT06241183

Locations in the U.S.

Conditions

• Indigestion
• GERD

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.